source
- Bristol Myers Squibb faces identity crisis as CEO Chris Boerner enters make-or-break yearBristol Myers Squibb is at a strategic crossroads as its chief executive, Chris Boerner, approaches the midway point of his tenure. After roughly two and a half years in the role, Boerner has over…
- Biogen seeks early-stage pipeline deals after $5.6 billion Apellis acquisitionBiogen announced it has earmarked $5.6 billion to acquire Apellis Pharmaceuticals, a move completed earlier this month. Despite the large transaction, the company says it will continue to explore…